Citius Pharmaceuticals, Inc.
CTXR
$0.85
$0.000.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.39% | 5.18% | 19.75% | 26.00% | 37.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.26% | 0.17% | 9.91% | 9.97% | 14.33% |
| Operating Income | 8.26% | -0.17% | -9.91% | -9.97% | -14.33% |
| Income Before Tax | 0.43% | -9.07% | -19.66% | -5.78% | -21.53% |
| Income Tax Expenses | 83.47% | 62.60% | 41.74% | 20.87% | 0.00% |
| Earnings from Continuing Operations | -0.80% | -9.87% | -20.01% | -6.01% | -21.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 703.62% | -- | -- | -- | -- |
| Net Income | 4.36% | -5.15% | -16.16% | -3.92% | -20.27% |
| EBIT | 8.26% | -0.17% | -9.91% | -9.97% | -14.33% |
| EBITDA | 8.26% | -0.17% | -9.92% | -9.98% | -14.33% |
| EPS Basic | 35.54% | 18.67% | 3.11% | 8.94% | -7.50% |
| Normalized Basic EPS | 40.73% | 24.96% | 10.74% | 3.77% | -3.37% |
| EPS Diluted | 35.54% | 19.27% | 5.76% | 11.26% | -4.36% |
| Normalized Diluted EPS | 40.73% | 24.96% | 10.74% | 3.77% | -3.37% |
| Average Basic Shares Outstanding | 64.55% | 31.81% | 19.95% | 13.46% | 11.16% |
| Average Diluted Shares Outstanding | 64.55% | 31.81% | 19.95% | 13.46% | 11.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |